Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics develops RNA medicines intended to restore protein expression, using its TANGO approach and antisense oligonucleotides for diseases caused by insufficient gene output. Its lead investigational medicine, zorevunersen, is in development for Dravet syndrome, with earlier work directed at rare genetic neurodevelopmental and other haploinsufficiency diseases.
Company news commonly covers zorevunersen clinical data, EMPEROR study updates, financial results, capital resources, collaboration activity, board and governance changes, equity inducement grants under Nasdaq rules, and healthcare conference presentations.
Stoke Therapeutics (Nasdaq: STOK) announced the first patient has been dosed in the Phase 1 OSPREY study of STK-002, an investigational antisense medicine for Autosomal Dominant Optic Atrophy (ADOA).
The dose-escalating, open-label study will enroll ages 6–55, assess safety, tolerability and blood exposure as primary endpoints, and evaluate visual function, ocular structure and quality of life as secondary objectives. Dose escalation for the first four cohorts continues through 2026 and early 2027. Approximately 80% of people with ADOA are symptomatic by age 10 and about 50% may become legally blind; no approved treatments currently exist.
Stoke Therapeutics (Nasdaq: STOK) announced that CEO Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 2:30 p.m. ET.
A live audio webcast and archived replay will be available in the Investors & News section of Stoke's investor website.
Stoke Therapeutics (NASDAQ: STOK) signed a long-term lease for a 98,500 square-foot headquarters at 245 Fifth Avenue in Waltham, MA, with occupancy planned after its Bedford lease ends in late 2026. The site is lab-ready and certified LEED Gold and WiredScore Platinum, and Anchor Line Partners and Northwood Investors secured the transaction. Stoke discovered its lead investigational medicine, zorevunersen (developed with Biogen), in Bedford and has advanced it into late-stage development for Dravet syndrome. Management says the move aims to support commercialization preparation and expanded research using Stoke’s RNA platform. Cushman & Wakefield represented Stoke in the lease.
The lease was noted as one of the largest Greater Boston life sciences transactions in the past year and emphasizes Waltham’s connectivity to Route 128/I-95, I-90 and Route 2.
Stoke Therapeutics (Nasdaq: STOK) granted inducement stock options effective January 15, 2026, to nine new employees covering an aggregate of 74,020 shares of common stock under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $29.28 per share (closing price on January 15, 2026), a 10-year term, and vest over four years: 25% at the one-year anniversary and the remainder monthly over 36 months, subject to continued employment and the 2023 Inducement Plan and option agreement terms.
Stoke Therapeutics (Nasdaq: STOK) and collaborator Biogen (Nasdaq: BIIB) updated timelines for zorevunersen in Dravet syndrome. Completion of enrollment of 150 patients in the Phase 3 EMPEROR study is now expected in Q2 2026, with a topline data readout planned for mid-2027 and a rolling NDA initiation targeted in the first half of 2027. A recent multidisciplinary FDA meeting raised requests for additional information; discussions are ongoing and no immediate program changes were agreed. As of Jan 9, 2026, ~60 patients are in screening, ~60 randomized/dosed, and the company held $391.7M in cash and equivalents, expected to fund operations into 2028.
Stoke Therapeutics (Nasdaq: STOK) announced that CEO Ian F. Smith will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 7:30 p.m. ET (4:30 p.m. PT).
A live audio webcast will be available on Stoke's Investors & News website and a replay will be accessible for 30 days after the presentation.
Stoke Therapeutics (Nasdaq: STOK) granted inducement stock options effective December 15, 2025 to eleven new employees totaling 131,280 shares of common stock.
The options carry an exercise price of $32.98 per share (equal to the closing price on December 15, 2025), vest over four years with 1/4 vesting on the one‑year anniversary and the remainder vesting monthly over the next 36 months, and have a 10‑year term. Grants are subject to the 2023 Inducement Plan and each employee’s option agreement.
Stoke Therapeutics and Biogen (Nasdaq: BIIB) will present new clinical and EEG analyses for zorevunersen at the 2025 American Epilepsy Society Annual Meeting (Dec 5–9, Atlanta).
Presentations report up to four years of data from Phase 1/2a and ongoing open‑label extension (OLE) studies, including propensity‑weighted analyses and EEG findings in patients with Dravet syndrome. Zorevunersen is also being evaluated in the global pivotal Phase 3 EMPEROR study in children and adolescents with Dravet syndrome.
Sessions include one oral presentation (Dec 5) and multiple posters (Dec 6–8) covering seizure outcomes, seizure‑free days, quality of life, overall functioning, and electrophysiological EEG changes linked to seizure reductions.
Stoke Therapeutics (Nasdaq: STOK) granted inducement stock options effective November 17, 2025 to Naomi Muse, newly appointed Senior Vice President, Program Leadership and Management, and six other new employees.
Key terms: 80,000 options to Ms. Muse and an aggregate of 156,490 options to six employees; exercise price $26.95 per share (closing price on November 17, 2025); options vest over 4 years (25% at one year, then monthly over 36 months); 10-year term; grants subject to the 2023 Inducement Plan and option agreements.
Stoke Therapeutics (Nasdaq: STOK) announced that CEO Ian F. Smith will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 at 9:00 a.m. ET.
The company is developing zorevunersen, a lead investigational medicine for Dravet syndrome that aims to restore protein expression using RNA medicine. A live webcast and archived replay of the presentation will be available in the Investors & News section of Stoke's website.